TransCode Therapeutics Ownership | Who Owns TransCode Therapeutics?

TransCode Therapeutics Ownership Summary

TransCode Therapeutics is owned by 0.09% institutional investors, and 99.91% retail investors. Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund, with 1.35% of its assets in TransCode Therapeutics shares.

RNAZ Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	TransCode Therapeutics	0.09%	-	99.91%
Sector	Healthcare Stocks	57.39%	9.93%	32.68%
Industry	Biotech Stocks	68.48%	9.65%	21.87%

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2023	11	-38.89%	262,198	-24.05%	-	633.44%	4	-73.33%	3	-
Dec 31, 2022	18	63.64%	345,210	-83.28%	-	18.95%	15	-	-	-100.00%
Sep 30, 2022	11	-8.33%	2,064,102	-0.99%	-	123.25%	-	-100.00%	3	50.00%
Jun 30, 2022	12	-	2,084,804	91.33%	-	455.76%	4	-	2	-50.00%
Mar 31, 2022	12	-14.29%	1,089,616	-53.71%	-	40.26%	4	-50.00%	4	300.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Institutional Extnd Mkt Idx Tr	9.38K	1.35%	9.38K
Fidelity Extended Market Index	2.81K	0.40%	-18.00
Northern Trust Extended Eq Market Idx	1.65K	0.24%	1.65K
NT Ext Equity Mkt Idx Fd - L	1.65K	0.24%	-
Fidelity Total Market Index	1.18K	0.17%	-
Fidelity Series Total Market Index	685.00	0.10%	-
NT Ext Eq Mkt Indx Fd DC Lending Tier 5	397.00	0.06%	3.00
NT Ext Eq Mkt Indx Fd DC Lend T3	394.00	0.06%	394.00
NT Ext Eq Mkt Indx Fd DC Lend T4	394.00	0.06%	394.00
Spartan Extended Market Index Pool F	49.00	0.01%	18.00

Insider Transactions Trends

Date	Buy	Sell
2023 Q2	4	-
2022 Q4	-	-
2022 Q3	1	-
2022 Q2	2	-
2022 Q1	-	-

RNAZ Ownership FAQ

Who Owns TransCode Therapeutics?

TransCode Therapeutics shareholders are primarily institutional investors at 0.09%, followed by 0% insiders and 0% retail investors. The average institutional ownership in TransCode Therapeutics's industry, Biotech Stocks , is 68.48%, which TransCode Therapeutics falls below.

Does Blackrock own TransCode Therapeutics?

BlackRock is not among the top 10 institutional shareholders of TransCode Therapeutics.

Who is the top mutual fund holder of TransCode Therapeutics shares?

Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund holder of TransCode Therapeutics shares, with 1.35% of its total shares outstanding invested in 9.38K TransCode Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools